Hemophilia A – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hemophilia A (US)

Hemophilia A, a monogenic X-linked recessive bleeding disorder, is caused by factor VIII deficiency. Current treatments include factor VIII recombinant therapies, bypass agents, Hemlibra, and vasopressin receptor agonists. Hemlibra has significantly transformed patient care by improving treatment outcomes, reducing dosing burden, and enabling convenient subcutaneous administration. Sanofi’s Altuviiio, a once-weekly factor VIII therapy, offers significant bleed protection with a half-life 3 to 4 times longer than standard and extended half-life factor VIII therapies, providing enhanced convenience and efficacy. In this report, we closely examine how key current therapies are being used in the treatment of newly diagnosed and recently treated hemophilia A patients in the United States.

Questions answered

• What percentage of hemophilia A patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?
• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed hemophilia A patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed hemophilia A patients?
• How has Altuviiio been integrated into the treatment algorithm, and what is its source of business? How has the inclusion of Altuviiio impacted other rFVIII?
• What percentage of hemophilia A patients are treated with monotherapy versus combination therapy? What are the most used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Markets covered: United States

Key drugs: Hemlibra, Roctavian, Altuviiio, Eloctate, Esperoct, Adynovate, Jivi, SHL FVIIIs

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

• Understand patient flow between lines of therapy.
• Evaluate your brand share against competitors.
• Accurately assess your source of business.
• Quantify opportunities at different stages of the treatment algorithm.

Key feature

Dashboard featuring interactive visuals, easy navigation, and expanded analyses